This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns
by Nalak Das
Three large-cap stocks ??? AES, PFE and UNM ??? currently offer attractive short-term returns along with a high dividend rate.
PFENegative Net Change UNMPositive Net Change AESNo Net Change
insurance pharmaceuticals utilities
Incyte Announces Promising New Data on Oncology Candidate at ESMO
by Zacks Equity Research
INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.
INCYNegative Net Change SNDXNegative Net Change KRYSNegative Net Change FULCNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
by Zacks Equity Research
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
by Zacks Equity Research
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
MRKNegative Net Change SMMTPositive Net Change TILPositive Net Change BVSPositive Net Change
biotechs medical pharmaceuticals
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
by Zacks Equity Research
Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage study.
ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change IMRXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
by Zacks Equity Research
As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.
SNYNegative Net Change GSKNegative Net Change MRKNegative Net Change MRNANegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
by Kinjel Shah
Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.
SNYNegative Net Change JNJNegative Net Change TEVANegative Net Change ABBVNegative Net Change
pharmaceuticals
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
by Zacks Equity Research
The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq Hybreza.
NVSNegative Net Change RHHBYNegative Net Change LLYPositive Net Change
biotechnology immuno-therapy medical pharmaceuticals
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
by Zacks Equity Research
GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.
GSKNegative Net Change GILDPositive Net Change KRYSNegative Net Change FULCNegative Net Change
biotechnology biotechs pharmaceuticals
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
by Kinjel Shah
FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.
REGNNegative Net Change SNYNegative Net Change JNJNegative Net Change NVONegative Net Change
pharmaceuticals
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
by Zacks Equity Research
AURA stock up as lead candidate shows tumor control and visual acuity preservation abilities in eye cancer patients over 12 months of treatment.
ILMNNegative Net Change KRYSNegative Net Change FULCNegative Net Change AURANegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
by Kinjel Shah
Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
pharmaceuticals
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
by Zacks Equity Research
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
GSKNegative Net Change SMMTPositive Net Change IMVTNegative Net Change RLAYNegative Net Change TERNNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy
by Zacks Equity Research
NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
by Zacks Equity Research
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
JNJNegative Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs immuno-therapy medical pharmaceuticals
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
by Ahan Chakraborty
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
NVSNegative Net Change RHHBYNegative Net Change PFENegative Net Change LLYPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug
by Zacks Equity Research
RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.
RHHBYNegative Net Change NVONegative Net Change LLYPositive Net Change
medical pharmaceuticals
Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Eli Lilly and Hertz Global have been highlighted as Zacks Bull and Bear of the Day.
AMZNPositive Net Change HTZNegative Net Change LLYPositive Net Change GOOGLPositive Net Change SHOPPositive Net Change
pharmaceuticals
Bull of the Day: Eli Lilly (LLY)
by Ethan Feller
Eli Lilly stock boasts both defensive and growth characteristics
LLYPositive Net Change
medical pharmaceuticals
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
by Zacks Equity Research
BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.
BMYPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
by Zacks Equity Research
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
REGNNegative Net Change SNYNegative Net Change NVSNegative Net Change RHHBYNegative Net Change
biotechs medical pharmaceuticals
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
by Zacks Equity Research
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
AZNNegative Net Change GSKNegative Net Change BIIBNegative Net Change IONSPositive Net Change
medical pharmaceuticals
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
by Zacks Equity Research
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
BMYPositive Net Change MRKNegative Net Change CRVSPositive Net Change FULCNegative Net Change
biotechnology biotechs medical pharmaceuticals
Top Stock Reports for Visa, AbbVie & Anheuser-Busch
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).
VNegative Net Change MCOPositive Net Change LLYPositive Net Change BUDNegative Net Change KMIPositive Net Change ABBVNegative Net Change SVTPositive Net Change UGPositive Net Change
business-services consumer-staples medical multi-sector-conglomerates pharmaceuticals
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
by Zacks Equity Research
Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
MRKNegative Net Change SMMTPositive Net Change FULCNegative Net Change BVSPositive Net Change
medical pharmaceuticals